Hi Jean.
I have provided a link and text below, to a discussion of the differences between the two taxanes you mentioned. As far as weekly vs. 3weekly Herceptin, I have always personally believed that spreading any drug out as evenly as possible would work best and have the least side effects. Therefore my vote is for weekly administration of Herceptin. I hope this helps.
Tom
http://www.lbbc.org/news-detail.asp?news_id=497
Breast Cancer News
Monday, March 06, 2006
Paclitaxel and Docetaxel Work Equally Well
Two taxanes show little difference in effectiveness, even when given on different dosing schedules
By Janine E. Guglielmino, LBBC Staff
Abstract #48, San Antonio Breast Cancer Symposium
A clinical trial that used different dosing and timing schedules to compare paclitaxel (brand name: Taxol) to docetaxel (brand name: Taxotere) showed little difference in disease-free survival for women with aggressive, early-stage breast cancer.
This study, presented at the 28th Annual San Antonio Breast Cancer Symposium, sought an answer to the long-standing question of which of these two chemotherapy treatments works more effectively. Both are approved for use after surgery in women with Stage II or Stage III breast cancer that has spread to the lymph nodes. However, no study has ever directly compared the treatments in weekly versus three-week dosing schedules.
What Are Paclitaxel and Docetaxel?
Paclitaxel and docetaxel are taxanes, medications originally derived from the yew tree. They work by slowing down or stopping the cell growth associated with some breast cancers. Taxanes are given in combination with or after other chemotherapy treatments.
Who Participated in the Study?
A total of 4,988 women enrolled in this study between 1999 and 2002. All participants had tumors of 2 centimeters or more with cancer that had either spread to the lymph nodes or was at high risk to do so.
After surgery, all women received four rounds of adriamycin and cytoxan chemotherapy. The women were then randomly assigned to receive one of four treatments: either paclitaxel or docetaxel given weekly for 12 weeks or every third week over 12 weeks. Women with estrogen receptor-positive breast cancer also received five years or longer of either tamoxifen or, if they were post-menopausal, an aromatase inhibitor. Researchers monitored the women's health for a median of four years or until they experienced a local, regional or distant recurrence, a second and unrelated breast cancer or died for reasons unrelated to breast cancer.
What the Results Showed
Among the four groups, the study showed no significant difference in disease-free survival. That means "doctors and patients will be able to consider side effects, convenience and cost in determining treatment without concern that effectiveness will be compromised," said
JoAnn Zujewski, MD, director of breast cancer clinical trials for the National Cancer Institute's cancer therapy evaluation program.
What This Study Means for You
If you are considering a taxane as part of your treatment for early-stage breast cancer, you may want to discuss this study with your doctor. The results show you may be able to receive taxanes either more or less frequently, depending on your health and your schedule. You may also choose the taxane treatment based on associated side effects and feel confident you and your doctor are making the best decision for your long-term health.
Read the abstract.